Coiled Therapeutics (AIM:COIL, OTCQB:COTXF) has strengthened the scientific bench behind its lead cancer drug candidate AO-252, appointing Professor Ozgur Sahin as scientific advisor as the programme approaches a series of clinical milestones. The AIM-listed oncology company said Sahin, a named inventor on foundational patents underpinning AO-252, is one of the world's leading authorities on TACC3 biology.